FDA Approves Luye Pharma’s Rykindo® for the Treatment of Schizophrenia and Bipolar 1 Disorder
Rykindo® is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma’s Central Nervous System (CNS) product portfolio to be marketed in the United States. PRINCETON, N.J., Jan. 15, 2023 /PRNewswire/ — Luye Pharma Group (Luye Pharma), an…
Comments Off on FDA Approves Luye Pharma’s Rykindo® for the Treatment of Schizophrenia and Bipolar 1 Disorder